Successful re-challenge of dabrafenib-trametinib combination therapy in advanced <i>BRAF</i> <sup>V600E</sup>-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.

Xue, Yaran; Ren, Yaqian; Yan, Bing; Li, Zhaona; Huang, Chun

Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF ^V600E-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.

Xue, Yaran; Ren, Yaqian; Yan, Bing; Li, Zhaona; Huang, Chun.

Affiliation

Xue Y; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Ren Y; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yan B; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Li Z; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Huang C; Department of Precision Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.

Ann Transl Med ; 10(18): 1029, 2022 Sep.

Article de En | MEDLINE | ID: mdl-36267742

Mots clés

BRAFV600E; D/T re-challenge; Non-small cell lung cancer (NSCLC); case report; immune checkpoint blockage (ICB)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Ann Transl Med Année: 2022 Type de document: Article Pays d'affiliation: Chine

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google